JP6158825B2 - テネイシンｃおよび関節リウマチにおけるその使用 - Google Patents

テネイシンｃおよび関節リウマチにおけるその使用 Download PDF

Info

Publication number
JP6158825B2
JP6158825B2 JP2014546631A JP2014546631A JP6158825B2 JP 6158825 B2 JP6158825 B2 JP 6158825B2 JP 2014546631 A JP2014546631 A JP 2014546631A JP 2014546631 A JP2014546631 A JP 2014546631A JP 6158825 B2 JP6158825 B2 JP 6158825B2
Authority
JP
Japan
Prior art keywords
rheumatoid arthritis
tenascin
level
patient
erosive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014546631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503106A (ja
JP2015503106A5 (enExample
Inventor
キム・スザンヌ・ミッドウッド
Original Assignee
オックスフォード ユニヴァーシティ イノヴェーション リミテッド
オックスフォード ユニヴァーシティ イノヴェーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121280A external-priority patent/GB201121280D0/en
Priority claimed from GBGB1214806.0A external-priority patent/GB201214806D0/en
Application filed by オックスフォード ユニヴァーシティ イノヴェーション リミテッド, オックスフォード ユニヴァーシティ イノヴェーション リミテッド filed Critical オックスフォード ユニヴァーシティ イノヴェーション リミテッド
Publication of JP2015503106A publication Critical patent/JP2015503106A/ja
Publication of JP2015503106A5 publication Critical patent/JP2015503106A5/ja
Application granted granted Critical
Publication of JP6158825B2 publication Critical patent/JP6158825B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014546631A 2011-12-12 2012-12-12 テネイシンｃおよび関節リウマチにおけるその使用 Expired - Fee Related JP6158825B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1121280.0 2011-12-12
GB201121280A GB201121280D0 (en) 2011-12-12 2011-12-12 Biomarker
GBGB1214806.0A GB201214806D0 (en) 2012-08-20 2012-08-20 Biomarker
GB1214806.0 2012-08-20
PCT/GB2012/053104 WO2013088140A2 (en) 2011-12-12 2012-12-12 Biomarker and use thereof

Publications (3)

Publication Number Publication Date
JP2015503106A JP2015503106A (ja) 2015-01-29
JP2015503106A5 JP2015503106A5 (enExample) 2015-12-10
JP6158825B2 true JP6158825B2 (ja) 2017-07-05

Family

ID=47561655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546631A Expired - Fee Related JP6158825B2 (ja) 2011-12-12 2012-12-12 テネイシンｃおよび関節リウマチにおけるその使用

Country Status (9)

Country Link
US (1) US20140322211A1 (enExample)
EP (1) EP2791686B1 (enExample)
JP (1) JP6158825B2 (enExample)
KR (1) KR20140109956A (enExample)
CN (1) CN104105967B (enExample)
BR (1) BR112014014295A2 (enExample)
CA (1) CA2894746A1 (enExample)
IN (1) IN2014MN01372A (enExample)
WO (1) WO2013088140A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400521D0 (en) 2014-01-13 2014-02-26 Isis Innovation Biomarker and uses thereof
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
KR101048894B1 (ko) * 2002-02-26 2011-07-13 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 항-인간 테나신 단클론 항체
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
KR100958840B1 (ko) * 2007-08-28 2010-05-24 단국대학교 산학협력단 항－테나신 c 펩타이드 및 그의 용도
EP2205977A1 (en) * 2007-10-22 2010-07-14 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Use of tenascin-w as a biomarker for colon cancer
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
AU2011253230B2 (en) * 2008-07-18 2014-07-17 Hill's Pet Nutrition, Inc. Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
JP5360922B2 (ja) * 2011-08-03 2013-12-04 国立大学法人山口大学 新規虚血マーカー及びこれを用いた虚血状態の検出方法

Also Published As

Publication number Publication date
WO2013088140A3 (en) 2013-08-08
US20140322211A1 (en) 2014-10-30
CA2894746A1 (en) 2013-06-20
EP2791686B1 (en) 2017-02-15
JP2015503106A (ja) 2015-01-29
HK1203232A1 (en) 2015-10-23
CN104105967A (zh) 2014-10-15
EP2791686A2 (en) 2014-10-22
BR112014014295A2 (pt) 2017-06-13
KR20140109956A (ko) 2014-09-16
CN104105967B (zh) 2017-03-08
WO2013088140A2 (en) 2013-06-20
IN2014MN01372A (enExample) 2015-04-17

Similar Documents

Publication Publication Date Title
US11598781B2 (en) Method for predicting the risk of incidence of chronic kidney disease
US20030175713A1 (en) Method for diagnosis of inflammatory diseases using CALGRANULIN C
Moniuszko et al. Biomarkers in management of inflammatory bowel disease
US7709215B2 (en) Method for diagnosing and treating acute joint injury
WO2016117618A1 (ja) 慢性炎症性脱髄性多発神経炎の診断方法、キット及びバイオマーカー
CN116064763B (zh) 以ifp35和nmi为靶点的疾病诊断和治疗
JP6158825B2 (ja) テネイシンｃおよび関節リウマチにおけるその使用
JP6687391B2 (ja) リウマチ性関節炎（ｒａ）の存在を決定するためのサンプルの測定方法
US10094826B2 (en) Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD
JP7620324B2 (ja) 炎症性腸疾患の診断方法、診断プローブ及び診断キット
Elsehmawy et al. Relation between interleukin-13 and annexin-V levels and carotid intima-media thickness in nephrotic syndrome
US10036746B2 (en) Method for the diagnosis of neuromyelitis optica
JP6555711B2 (ja) 非解離性大動脈瘤の疾患活動性の判定方法
KR20210055856A (ko) 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용
HK1203232B (en) Tenascin-c and use thereof in rheumatoid arthritis
RU2755492C1 (ru) Способ прогнозирования риска развития рецидива язвенного колита
WO2024213795A1 (en) Diagnosis method using cell free nucleosome levels
CN118746694A (zh) 中性粒细胞胞外诱捕网血浆蛋白标记物在抑郁症诊疗中的应用
WO2012098256A1 (en) Anti-cd146 auto-antibodies and uses thereof
Javed Investigation of Potential Biomarkers for Lymphangioleiomyomatosis (Lam) in Blood
van de Sande et al. ven
HK1250779B (zh) 用於预测慢性肾病发生风险的方法
UA113328C2 (uk) Спосіб діагностики активного системного червоного вовчака
EP3056904A1 (en) Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-MCM3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170608

R150 Certificate of patent or registration of utility model

Ref document number: 6158825

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees